Markus Riester
Overview
Explore the profile of Markus Riester including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
3422
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dimitrieva S, Harrison J, Chang J, Piquet M, Mino-Kenudson M, Gabriel M, et al.
Cancer Res Commun
. 2024 Nov;
4(12):3049-3066.
PMID: 39485038
Pancreatic cancer remains a high unmet medical need. Understanding the interactions between stroma and cancer cells in this disease may unveil new opportunities for therapeutic intervention.
2.
Cotton J, Estrada Diez J, Sagar V, Chen J, Piquet M, Alford J, et al.
Cancer Res
. 2023 Aug;
83(21):3611-3623.
PMID: 37603596
Significance: The evolution and heterogeneity of EGFR inhibitor tolerance are identified in a large number of clones at enhanced cellular and temporal resolution using an expressed barcode technology coupled with...
3.
Oh S, Abdelnabi J, Al-Dulaimi R, Aggarwal A, Ramos M, Davis S, et al.
F1000Res
. 2022 Jun;
9:1493.
PMID: 33564398
Gene symbols are recognizable identifiers for gene names but are unstable and error-prone due to aliasing, manual entry, and unintentional conversion by spreadsheets to date format. Official gene symbol resources...
4.
Chan S, Schuler M, Kang Y, Yen C, Edeline J, Choo S, et al.
J Exp Clin Cancer Res
. 2022 Jun;
41(1):189.
PMID: 35655320
Background: Deregulation of FGF19-FGFR4 signaling is found in several cancers, including hepatocellular carcinoma (HCC), nominating it for therapeutic targeting. FGF401 is a potent, selective FGFR4 inhibitor with antitumor activity in...
5.
Grauel A, Nguyen B, Ruddy D, Laszewski T, Schwartz S, Chang J, et al.
Nat Commun
. 2020 Dec;
11(1):6315.
PMID: 33298926
Despite the increasing interest in targeting stromal elements of the tumor microenvironment, we still face tremendous challenges in developing adequate therapeutics to modify the tumor stromal landscape. A major obstacle...
6.
Geistlinger L, Oh S, Ramos M, Schiffer L, LaRue R, Henzler C, et al.
Cancer Res
. 2020 Aug;
80(20):4335-4345.
PMID: 32747365
Multiple studies have identified transcriptome subtypes of high-grade serous ovarian carcinoma (HGSOC), but their interpretation and translation are complicated by tumor evolution and polyclonality accompanied by extensive accumulation of somatic...
7.
Oh S, Geistlinger L, Ramos M, Morgan M, Waldron L, Riester M
JCO Clin Cancer Inform
. 2020 Apr;
4:321-335.
PMID: 32282230
Purpose: Allele-specific copy number alteration (CNA) analysis is essential to study the functional impact of single-nucleotide variants (SNVs) and the process of tumorigenesis. However, controversy over whether it can be...
8.
Yao J, Garg A, Chen D, Capdevila J, Engstrom P, Pommier R, et al.
Endocr Relat Cancer
. 2019 Jan;
26(4):391-403.
PMID: 30667365
Neuroendocrine tumors (NETs) have historically been subcategorized according to histologic features and the site of anatomic origin. Here, we characterize the genomic alterations in patients enrolled in 3 phase 3...
9.
Pitt J, Riester M, Zheng Y, Yoshimatsu T, Sanni A, Oluwasola O, et al.
Nat Commun
. 2019 Jan;
10(1):288.
PMID: 30643118
The original version of this Article contained an error in the author affiliations. The affiliation of Kevin P. White with Tempus Labs, Inc. Chicago, IL, USA was inadvertently omitted. This...
10.
Pitt J, Riester M, Zheng Y, Yoshimatsu T, Sanni A, Oluwasola O, et al.
Nat Commun
. 2018 Oct;
9(1):4181.
PMID: 30327465
Racial/ethnic disparities in breast cancer mortality continue to widen but genomic studies rarely interrogate breast cancer in diverse populations. Through genome, exome, and RNA sequencing, we examined the molecular features...